Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Catumaxomab

EU orphan designation number: EU/3/06/414   
Active ingredient: Catumaxomab
Indication: Treatment of gastric cancer
Sponsor: Neovii Biotech GmbH
Am Haag 6-7, 82166 Graefelfing, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/11/2006 Centralised Orphan - Designation EMEA/OD/044/06 (2006)5374 of 03/11/2006
24/01/2014 Centralised Orphan - Change of address